Advertisement
UK markets close in 6 hours 31 minutes

  • FTSE 100

    8,083.87
    +39.06 (+0.49%)
     

  • FTSE 250

    19,797.61
    -2.11 (-0.01%)
     

  • AIM

    755.55
    +0.68 (+0.09%)
     

  • GBP/EUR

    1.1630
    +0.0002 (+0.01%)
     

  • GBP/USD

    1.2426
    -0.0027 (-0.21%)
     

  • Bitcoin GBP

    53,560.71
    +320.43 (+0.60%)
     

  • CMC Crypto 200

    1,434.84
    +10.74 (+0.75%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    83.11
    -0.25 (-0.30%)
     

  • GOLD FUTURES

    2,331.00
    -11.10 (-0.47%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,212.91
    +75.26 (+0.41%)
     

  • CAC 40

    8,124.59
    +18.81 (+0.23%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

BUZZ-Regulus Inc: Drug to be tested by AstraZeneca

Reuters - UK Focus

** Drug developer's shares up 9.4 pct at $17.45 in extended trading

** Company says Astrazeneca Plc (NYSE: AZN - news) selected its experimental drug, RG-125, for early-stage trial on Non Alcoholic Steatohepatitis (NASH) patients, as part of a strategic alliance signed in 2012

** AstraZeneca to pay Regulus $2.5 mln and initiate early-stage study by end of 2015

** Regulus and AstraZeneca formed alliance to develop microRNA therapeutics for cardiovascular and metabolic diseases as well as oncology

** Up to Tuesday's close, the stock had risen about 140 pct since Regulus announced a collaboration agreement with Biogen (Swiss: BIIB.SW - news) Idec on August 5